Skip to main content
PMC home page
Sexually Transmitted Infections logoLink to Sexually Transmitted Infections
. 2001 Feb;77(1):4–11. doi: 10.1136/sti.77.1.4

Antiretroviral drug concentrations in semen of HIV-1 infected men

S Taylor 1, A Pereira 1
PMCID: PMC1758331  PMID: 11158684

Abstract

website extra A table detailing antiretroviral drugs appears on the STI website. www.sextransinf.com

Because semen is a major vehicle for the sexual transmission of HIV-1, control of viral replication within the sanctuary of the male genital tract should be a goal of antiretroviral therapy. Local immune responses, virus specific factors, and the degree of viral and cellular trafficking all appear to be important in controlling viral replication and evolution. However, the most important factor influencing viral replication and evolution within the male genital tract may be the disposition of antiretroviral agents into genital tissues and fluids. This review proposes possible mechanisms of antiretroviral distribution into the male genital tract by using other sanctuary barriers; such as the placenta, renal tubules, and blood-brain barrier; as models. In addition, this review summarises recent clinical studies regarding the disposition of currently available antiretroviral drugs into the seminal plasma and discusses some of the difficulties in interpreting drug concentration in the genital tract.

Key Words: HIV; semen; antiretrovirals; drug concentrations; pharmacokinetics; protein binding

Full Text

The Full Text of this article is available as a PDF (729.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aiba T., Sakurai Y., Tsukada S., Koizumi T. Effects of probenecid and cimetidine on the renal excretion of 3'-azido-3'-deoxythymidine in rats. J Pharmacol Exp Ther. 1995 Jan;272(1):94–99. [PubMed] [Google Scholar]
  2. Anderson D. J., O'Brien T. R., Politch J. A., Martinez A., Seage G. R., 3rd, Padian N., Horsburgh C. R., Jr, Mayer K. H. Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen. JAMA. 1992 May 27;267(20):2769–2774. [PubMed] [Google Scholar]
  3. Anderson P. L., Noormohamed S. E., Henry K., Brundage R. C., Balfour H. H., Jr, Fletcher C. V. Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection. Pharmacotherapy. 2000 Aug;20(8):917–922. doi: 10.1592/phco.20.11.917.35263. [DOI] [PubMed] [Google Scholar]
  4. Bendayan R., Georgis W., Rafi-Tari S. Interaction of 3'-azido-3'-deoxythymidine with the organic base transporter in a cultured renal epithelium. Pharmacotherapy. 1995 May-Jun;15(3):338–344. [PubMed] [Google Scholar]
  5. Bloom S. L., Dias K. M., Bawdon R. E., Gilstrap L. C., 3rd The maternal-fetal transfer of lamivudine in the ex vivo human placenta. Am J Obstet Gynecol. 1997 Feb;176(2):291–293. doi: 10.1016/s0002-9378(97)70487-3. [DOI] [PubMed] [Google Scholar]
  6. Boal J. H., Plessinger M. A., van den Reydt C., Miller R. K. Pharmacokinetic and toxicity studies of AZT (zidovudine) following perfusion of human term placenta for 14 hours. Toxicol Appl Pharmacol. 1997 Mar;143(1):13–21. doi: 10.1006/taap.1996.8046. [DOI] [PubMed] [Google Scholar]
  7. Boden D., Hurley A., Zhang L., Cao Y., Guo Y., Jones E., Tsay J., Ip J., Farthing C., Limoli K. HIV-1 drug resistance in newly infected individuals. JAMA. 1999 Sep 22;282(12):1135–1141. doi: 10.1001/jama.282.12.1135. [DOI] [PubMed] [Google Scholar]
  8. Byrn R. A., Zhang D., Eyre R., McGowan K., Kiessling A. A. HIV-1 in semen: an isolated virus reservoir. Lancet. 1997 Oct 18;350(9085):1141–1141. doi: 10.1016/S0140-6736(97)24042-0. [DOI] [PubMed] [Google Scholar]
  9. Chan S., Gerson B. Free drug monitoring. Clin Lab Med. 1987 Jun;7(2):279–287. [PubMed] [Google Scholar]
  10. Chatton J. Y., Odone M., Besseghir K., Roch-Ramel F. Renal secretion of 3'-azido-3'-deoxythymidine by the rat. J Pharmacol Exp Ther. 1990 Oct;255(1):140–145. [PubMed] [Google Scholar]
  11. Delwart E. L., Mullins J. I., Gupta P., Learn G. H., Jr, Holodniy M., Katzenstein D., Walker B. D., Singh M. K. Human immunodeficiency virus type 1 populations in blood and semen. J Virol. 1998 Jan;72(1):617–623. doi: 10.1128/jvi.72.1.617-623.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Eron J. J., Vernazza P. L., Johnston D. M., Seillier-Moiseiwitsch F., Alcorn T. M., Fiscus S. A., Cohen M. S. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS. 1998 Oct 22;12(15):F181–F189. doi: 10.1097/00002030-199815000-00003. [DOI] [PubMed] [Google Scholar]
  13. Foudraine N. A., Hoetelmans R. M., Lange J. M., de Wolf F., van Benthem B. H., Maas J. J., Keet I. P., Portegies P. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet. 1998 May 23;351(9115):1547–1551. doi: 10.1016/S0140-6736(98)07333-4. [DOI] [PubMed] [Google Scholar]
  14. Frick J., Aulitzky W. Physiology of the prostate. Infection. 1991;19 (Suppl 3):S115–S118. doi: 10.1007/BF01643679. [DOI] [PubMed] [Google Scholar]
  15. Gallicano K. Antiretroviral-drug concentrations in semen. Antimicrob Agents Chemother. 2000 Apr;44(4):1117–1118. doi: 10.1128/aac.44.4.1117-1118.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Glynn S. L., Yazdanian M. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J Pharm Sci. 1998 Mar;87(3):306–310. doi: 10.1021/js970291i. [DOI] [PubMed] [Google Scholar]
  17. Griffiths D. A., Hall S. D., Sokol P. P. Effect of 3'-azido-3'-deoxythymidine (AZT) on organic ion transport in rat renal brush border membrane vesicles. J Pharmacol Exp Ther. 1992 Jan;260(1):128–133. [PubMed] [Google Scholar]
  18. Griffiths D. A., Hall S. D., Sokol P. P. Interaction of 3'-azido-3'-deoxythymidine with organic ion transport in rat renal basolateral membrane vesicles. J Pharmacol Exp Ther. 1991 Apr;257(1):149–155. [PubMed] [Google Scholar]
  19. Hecht F. M., Grant R. M., Petropoulos C. J., Dillon B., Chesney M. A., Tian H., Hellmann N. S., Bandrapalli N. I., Digilio L., Branson B. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998 Jul 30;339(5):307–311. doi: 10.1056/NEJM199807303390504. [DOI] [PubMed] [Google Scholar]
  20. Henry K., Chinnock B. J., Quinn R. P., Fletcher C. V., de Miranda P., Balfour H. H., Jr Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. JAMA. 1988 May 27;259(20):3023–3026. [PubMed] [Google Scholar]
  21. Kashuba A. D., Dyer J. R., Kramer L. M., Raasch R. H., Eron J. J., Cohen M. S. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1999 Aug;43(8):1817–1826. doi: 10.1128/aac.43.8.1817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kim A. E., Dintaman J. M., Waddell D. S., Silverman J. A. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther. 1998 Sep;286(3):1439–1445. [PubMed] [Google Scholar]
  23. Kim R. B., Fromm M. F., Wandel C., Leake B., Wood A. J., Roden D. M., Wilkinson G. R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998 Jan 15;101(2):289–294. doi: 10.1172/JCI1269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Krieger J. N., Coombs R. W., Collier A. C., Ross S. O., Chaloupka K., Cummings D. K., Murphy V. L., Corey L. Recovery of human immunodeficiency virus type 1 from semen: minimal impact of stage of infection and current antiviral chemotherapy. J Infect Dis. 1991 Feb;163(2):386–388. doi: 10.1093/infdis/163.2.386. [DOI] [PubMed] [Google Scholar]
  25. Kroodsma K. L., Kozal M. J., Hamed K. A., Winters M. A., Merigan T. C. Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA. J Infect Dis. 1994 Nov;170(5):1292–1295. doi: 10.1093/infdis/170.5.1292. [DOI] [PubMed] [Google Scholar]
  26. Kwong T. C. Free drug measurements: methodology and clinical significance. Clin Chim Acta. 1985 Oct 15;151(3):193–216. doi: 10.1016/0009-8981(85)90082-8. [DOI] [PubMed] [Google Scholar]
  27. Lee C. G., Gottesman M. M., Cardarelli C. O., Ramachandra M., Jeang K. T., Ambudkar S. V., Pastan I., Dey S. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 1998 Mar 17;37(11):3594–3601. doi: 10.1021/bi972709x. [DOI] [PubMed] [Google Scholar]
  28. Little S. J., Daar E. S., D'Aquila R. T., Keiser P. H., Connick E., Whitcomb J. M., Hellmann N. S., Petropoulos C. J., Sutton L., Pitt J. A. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA. 1999 Sep 22;282(12):1142–1149. doi: 10.1001/jama.282.12.1142. [DOI] [PubMed] [Google Scholar]
  29. Luzier A., Morse G. D. Intravascular distribution of zidovudine: role of plasma proteins and whole blood components. Antiviral Res. 1993 Jul;21(3):267–280. doi: 10.1016/0166-3542(93)90032-e. [DOI] [PubMed] [Google Scholar]
  30. Madsen P. O., Aagaard J. Pharmacokinetics of quinolone derivatives in the prostate. Infection. 1991;19 (Suppl 3):S154–S156. doi: 10.1007/BF01643687. [DOI] [PubMed] [Google Scholar]
  31. Mann T., Lutwak-Mann C. Passage of chemicals into human and animal semen: mechanisms and significance. Crit Rev Toxicol. 1982;11(1):1–14. doi: 10.3109/10408448209089846. [DOI] [PubMed] [Google Scholar]
  32. Martin C., Sönnerborg A., Svensson J. O., Ståhle L. Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. AIDS. 1999 Jul 9;13(10):1227–1232. doi: 10.1097/00002030-199907090-00012. [DOI] [PubMed] [Google Scholar]
  33. Molla A., Vasavanonda S., Kumar G., Sham H. L., Johnson M., Grabowski B., Denissen J. F., Kohlbrenner W., Plattner J. J., Leonard J. M. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology. 1998 Oct 25;250(2):255–262. doi: 10.1006/viro.1998.9383. [DOI] [PubMed] [Google Scholar]
  34. Moore K. H., Barrett J. E., Shaw S., Pakes G. E., Churchus R., Kapoor A., Lloyd J., Barry M. G., Back D. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS. 1999 Nov 12;13(16):2239–2250. doi: 10.1097/00002030-199911120-00006. [DOI] [PubMed] [Google Scholar]
  35. Pereira A. S., Kashuba A. D., Fiscus S. A., Hall J. E., Tidwell R. R., Troiani L., Dunn J. A., Eron J. J., Jr, Cohen M. S. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J Infect Dis. 1999 Dec;180(6):2039–2043. doi: 10.1086/315149. [DOI] [PubMed] [Google Scholar]
  36. Pichini S., Zuccaro P., Pacifici R. Drugs in semen. Clin Pharmacokinet. 1994 May;26(5):356–373. doi: 10.2165/00003088-199426050-00004. [DOI] [PubMed] [Google Scholar]
  37. Polli J. W., Jarrett J. L., Studenberg S. D., Humphreys J. E., Dennis S. W., Brouwer K. R., Woolley J. L. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res. 1999 Aug;16(8):1206–1212. doi: 10.1023/a:1018941328702. [DOI] [PubMed] [Google Scholar]
  38. Rolinski B., Bogner J. R., Sadri I., Wintergerst U., Goebel F. D. Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Jul 1;15(3):192–197. doi: 10.1097/00042560-199707010-00002. [DOI] [PubMed] [Google Scholar]
  39. Routledge P. A. Factors contributing to variability in drug pharmacokinetics. II. Drug distribution. J Clin Hosp Pharm. 1985 Mar;10(1):15–23. doi: 10.1111/j.1365-2710.1985.tb00713.x. [DOI] [PubMed] [Google Scholar]
  40. Royce R. A., Seña A., Cates W., Jr, Cohen M. S. Sexual transmission of HIV. N Engl J Med. 1997 Apr 10;336(15):1072–1078. doi: 10.1056/NEJM199704103361507. [DOI] [PubMed] [Google Scholar]
  41. Spector R., Huntoon S. Specificity and sodium dependence of the active nucleoside transport system in choroid plexus. J Neurochem. 1984 Apr;42(4):1048–1052. doi: 10.1111/j.1471-4159.1984.tb12709.x. [DOI] [PubMed] [Google Scholar]
  42. Stewart P. A., Béliveau R., Rogers K. A. Cellular localization of P-glycoprotein in brain versus gonadal capillaries. J Histochem Cytochem. 1996 Jul;44(7):679–685. doi: 10.1177/44.7.8675989. [DOI] [PubMed] [Google Scholar]
  43. Tachet A., Dulioust E., Salmon D., De Almeida M., Rivalland S., Finkielsztejn L., Heard I., Jouannet P., Sicard D., Rouzioux C. Detection and quantification of HIV-1 in semen: identification of a subpopulation of men at high potential risk of viral sexual transmission. AIDS. 1999 May 7;13(7):823–831. doi: 10.1097/00002030-199905070-00012. [DOI] [PubMed] [Google Scholar]
  44. Takasawa K., Terasaki T., Suzuki H., Ooie T., Sugiyama Y. Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. J Pharmacol Exp Ther. 1997 Sep;282(3):1509–1517. [PubMed] [Google Scholar]
  45. Takasawa K., Terasaki T., Suzuki H., Sugiyama Y. In vivo evidence for carrier-mediated efflux transport of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. J Pharmacol Exp Ther. 1997 Apr;281(1):369–375. [PubMed] [Google Scholar]
  46. Taylor S., Back D. J., Workman J., Drake S. M., White D. J., Choudhury B., Cane P. A., Beards G. M., Halifax K., Pillay D. Poor penetration of the male genital tract by HIV-1 protease inhibitors. AIDS. 1999 May 7;13(7):859–860. doi: 10.1097/00002030-199905070-00017. [DOI] [PubMed] [Google Scholar]
  47. Taylor S., van Heeswijk R. P., Hoetelmans R. M., Workman J., Drake S. M., White D. J., Pillay D. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. AIDS. 2000 Sep 8;14(13):1979–1984. doi: 10.1097/00002030-200009080-00014. [DOI] [PubMed] [Google Scholar]
  48. Thomas S. A., Segal M. B. Saturation kinetics, specificity and NBMPR sensitivity of thymidine entry into the central nervous system. Brain Res. 1997 Jun 20;760(1-2):59–67. doi: 10.1016/s0006-8993(97)00276-x. [DOI] [PubMed] [Google Scholar]
  49. Thomas S. A., Segal M. B. The passage of azidodeoxythymidine into and within the central nervous system: does it follow the parent compound, thymidine? J Pharmacol Exp Ther. 1997 Jun;281(3):1211–1218. [PubMed] [Google Scholar]
  50. Vernazza P. L., Eron J. J., Fiscus S. A., Cohen M. S. Sexual transmission of HIV: infectiousness and prevention. AIDS. 1999 Feb 4;13(2):155–166. doi: 10.1097/00002030-199902040-00003. [DOI] [PubMed] [Google Scholar]
  51. Vernazza P. L., Gilliam B. L., Flepp M., Dyer J. R., Frank A. C., Fiscus S. A., Cohen M. S., Eron J. J. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS. 1997 Aug;11(10):1249–1254. doi: 10.1097/00002030-199710000-00008. [DOI] [PubMed] [Google Scholar]
  52. Winter A. J., Taylor S., Workman J., White D., Ross J. D., Swan A. V., Pillay D. Asymptomatic urethritis and detection of HIV-1 RNA in seminal plasma. Sex Transm Infect. 1999 Aug;75(4):261–263. doi: 10.1136/sti.75.4.261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Wu D., Clement J. G., Pardridge W. M. Low blood-brain barrier permeability to azidothymidine (AZT), 3TC, and thymidine in the rat. Brain Res. 1998 Apr 27;791(1-2):313–316. doi: 10.1016/s0006-8993(98)00139-5. [DOI] [PubMed] [Google Scholar]
  54. Zhang H., Dornadula G., Beumont M., Livornese L., Jr, Van Uitert B., Henning K., Pomerantz R. J. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med. 1998 Dec 17;339(25):1803–1809. doi: 10.1056/NEJM199812173392502. [DOI] [PubMed] [Google Scholar]
  55. Zhang X. Q., Schooley R. T., Gerber J. G. The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors. J Infect Dis. 1999 Dec;180(6):1833–1837. doi: 10.1086/315123. [DOI] [PubMed] [Google Scholar]
  56. van Asperen J., Mayer U., van Tellingen O., Beijnen J. H. The functional role of P-glycoprotein in the blood-brain barrier. J Pharm Sci. 1997 Aug;86(8):881–884. doi: 10.1021/js9701364. [DOI] [PubMed] [Google Scholar]
  57. van Praag R. M., Weverling G. J., Portegies P., Jurriaans S., Zhou X. J., Turner-Foisy M. L., Sommadossi J. P., Burger D. M., Lange J. M., Hoetelmans R. M. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS. 2000 Jun 16;14(9):1187–1194. doi: 10.1097/00002030-200006160-00016. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

[Additional Tables]
straninf_77_1_4__index.html (620B, html)
straninf_77_1_4__00102a.gif (248.4KB, gif)
straninf_77_1_4__00102b.gif (16.8KB, gif)

Articles from Sexually Transmitted Infections are provided here courtesy of BMJ Publishing Group

RESOURCES